In view of the promising results obtained when challenging PBMC from healthy donors with hiTG, we evaluated whether the generation of CIK cells from cancer patient-derived PBMC could be successfully pursued under the same experimental conditions (priming with IFN-γ on day 0 and then with IL-2 and TG on day +1). This evidence concerns the gene IFNG and cancer.